Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Subscribe To Our Newsletter & Stay Updated
